Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain.
Lehto J, Hirvonen MM, Johansson J, Kemppainen J, Luoto P, Naukkarinen T, Oikonen V, Arponen E, Rouru J, Sallinen J, Scheinin H, Vuorilehto L, Finnema SJ, Halldin C, Rinne JO, Scheinin M. Lehto J, et al. Synapse. 2015 Mar;69(3):172-81. doi: 10.1002/syn.21798. Epub 2015 Jan 8. Synapse. 2015. PMID: 25530024
This study explored the use of the alpha2C -adrenoceptor PET tracer [(11) C]ORM-13070 to monitor alpha2C -AR occupancy in the human brain. ...These findings represent clear support for the use of [(11) C]ORM-13070
This study explored the use of the alpha2C -adrenoceptor PET tracer [(11) C]ORM-13070 to monitor alpha
Application of the PET ligand [(11)C]ORM-13070 to examine receptor occupancy by the alpha(2C)-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain.
Shahid M, Rinne JO, Scheinin M, Virta J, Marjamäki P, Solin O, Arponen E, Sallinen J, Kuokkanen K, Rouru J. Shahid M, et al. EJNMMI Res. 2020 Dec 9;10(1):152. doi: 10.1186/s13550-020-00741-y. EJNMMI Res. 2020. PMID: 33296042 Free PMC article.
BACKGROUND: Availability of the alpha(2C)-adrenoceptor (alpha(2C)-AR) positron emission tomography (PET) tracer, [(11)C]ORM-13070, and the alpha(2C)-AR antagonist ORM-12741 allows probing of the roles of this G-protein coupled receptor subtype i …
BACKGROUND: Availability of the alpha(2C)-adrenoceptor (alpha(2C)-AR) positron emission tomography (PET) tracer, [(11)C]ORM
11C-ORM-13070, a novel PET ligand for brain alpha2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.
Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO. Luoto P, et al. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24838249
PURPOSE: (11)C-labelled 1-[(S)-1-(2,3-dihydrobenzo[1,2]dioxin-2-yl)methyl]-4-(3-methoxy-methylpyridin-2-yl)-piperazine ((11)C-ORM-13070) is a novel …
PURPOSE: (11)C-labelled 1-[(S)-1-(2,3-dihydrobenzo[1,2]dioxin-2-yl